Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes

British Journal of Surgery

Volumn 100, Issue 8, 2013, Pages

  Bhangu, A ^a   Beynon, J ^a   Brown, G ^a   Chang, G ^a   Das, P ^a   Desai, A ^a   Frizelle, F ^a   Glynne Jones, R ^a   Goldin, R ^a   Hawkins, M A ^a   Heriot, A ^a   Laurberg, S ^a   Mirnezami, A ^a   Moran, B ^a   Nicholls, R J ^a   Sagar, P ^a   Tekkis, P ^a,b   Vuong, T ^a   Wilson, M ^a   Ali, S M ^a   Antoniou, A ^a   Bose, P ^a   Boyle, K ^a   Branagan, G ^a   Burling, D ^a   Clark, S K ^a   Colquhoun, P ^a   Crane, C H ^a   Darzi, A ^a   Davies, M ^a   Delaney, C P ^a   Dietz, D ^a   Dozois, E J ^a   Duff, M ^a   Dziki, A ^a   Faria, J ^a   Fitzgerald, J E ^a   Georgiou, P ^a   George, B ^a   George, M L ^a   Gupta, A ^a   Guy, R ^a   Harji, D P ^a   Harris, D A ^a   Herzig, D ^a   Holm, T ^a   Hompes, R ^a   Jeys, L ^a   Jenkins, J T ^a   Kiran, R P ^a   Koh, C E ^a   Law, W L ^a   Liberman, A S ^a   Marshall, M ^a   McArthur, D R ^a   Mortensen, N ^a   Myers, E ^a   O'Connell, P R ^a   O'Dwyer, S T ^a   Oliver, A ^a   Pallan, A ^a   Patel, P ^a   Patel, U B ^a   Radley, S ^a   Ramsey, K W D ^a   Rasmussen, P C ^a   Richard, C ^a   Rutten, H J T ^a   Sebag Montefiore, D ^a   Solomon, M J ^a   Stocchi, L ^a   Swallow, C J ^a   Tait, D M ^a   Tan, E ^a   Van As, N ^a   Wiggers, T ^a   de Wilt, J H W ^a   Winter, D C ^a   Woodhouse, C ^a   more..

^a The Royal Marsden Hospital ^*

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896058553     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9192_1     Document Type: Review

References (149)

1. Rowe G, Wright G,. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast 1999; 4: 353-375.
2. Harbour R, Miller J,. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-336.
3. Kau T, Reinprecht P, Eicher W, Lind P, Starlinger M, Hausegger KA,. FDG PET/CT in the detection of recurrent rectal cancer. Int Surg 2009; 94: 315-324.
4. Kusters M, Dresen RC, Martijn H, Nieuwenhuijzen GA, van de Velde CJ, van den Berg HA, et al. Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2009; 75: 1444-1449.
5. Park JK, Kim YW, Hur H, Kim NK, Min BS, Sohn SK, et al. Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection. Langenbecks Arch Surg 2009; 394: 71-77.
6. Georgiou PA, Tekkis PP, Constantinides VA, Patel U, Goldin RD, Darzi AW, et al. Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. Eur J Cancer 2013; 49: 72-81.
7. Moran B, Brown G, Cunningham D, Daniels I, Heald R, Quirke P, et al. Clarifying the TNM staging of rectal cancer in the context of modern imaging and neo-adjuvant treatment: 'y"u' and 'p' need 'mr' and 'ct'. Colorectal Dis 2008; 10: 242-243.
8. Puli SR, Bechtold ML, Reddy JB, Choudhary A, Antillon MR, Brugge WR,. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009; 16: 254-265.
9. Mirnezami AH, Sagar PM, Kavanagh D, Witherspoon P, Lee P, Winter D,. Clinical algorithms for the surgical management of locally recurrent rectal cancer. Dis Colon Rectum 2010; 53: 1248-1257.
10. Kelvin FM, Korobkin M, Heaston DK, Grant JP, Akwari O,. The pelvis after surgery for rectal carcinoma: serial CT observations with emphasis on nonneoplastic features. AJR Am J Roentgenol 1983; 141: 959-964.
11. Rifkin MD, Ehrlich SM, Marks G,. Staging of rectal carcinoma: prospective comparison of endorectal US and CT. Radiology 1989; 170: 319-322.
12. Adalsteinsson B, Påhlman L, Hemmingsson A, Glimelius B, Graffman S,. Computed tomography in early diagnosis of local recurrence of rectal carcinoma. Acta Radiologica 1987; 28: 41-47.
13. Watson AJ, Lolohea S, Robertson GM, Frizelle FA,. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum 2007; 50: 102-114.
14. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC,. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007; 13: 5025-5029.
15. Kochhar R, Liong S, Manoharan P,. The role of FDG PET/CT in patients with colorectal cancer metastases. Cancer Biomark 2010; 7: 235-248.
16. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al.; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
17. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644.
18. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-1933.
19. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687-3694.
20. Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL,. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1981-1987.
21. Vuong T, Niazi T, Letellier F, Richard C, Liberman S, Faria J, et al. A Dose Escalation Phase II Study Using Intensity Modulated Radiation Therapy (IMRT) and Concurrent Chemotherapy For Patients With Advanced Rectal Cancer And Magnetic Resonant Imaging (MRI) Defined Positive Circumferential Radial Margins (CRM+). Int J Radiat Oncol Biol Phy 81: S225; ASTRO 2011 proceeding.
22. Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ,. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy 2010; 9: 66-70.
23. Suzuki K, Gunderson LL, Devine RM, Weaver AL, Dozois RR, Ilstrup DM, et al. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 1995; 75: 939-952.
24. Kusters M, Holman FA, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, et al. Patterns of local recurrence in locally advanced rectal cancer after intra-operative radiotherapy containing multimodality treatment. Radiother Oncol 2009; 92: 221-225.
25. James RD, Johnson RJ, Eddleston B, Zheng GL, Jones JM,. Prognostic factors in locally recurrent rectal carcinoma treated by radiotherapy. Br J Surg 1983; 70: 469-472.
26. Mohiuddin M, Marks GM, Lingareddy V, Marks J,. Curative surgical resection following reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys 1997; 39: 643-649.
27. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Ståhl E,. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-492.
28. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 2010; 77: 60-65.
29. Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, et al.; StudyGroup for Therapies of Rectal Malignancies (STORM). Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiat Oncol Biol Phys 2006; 64: 1129-1139.
30. Frykholm GJ, Påhlman L, Glimelius B,. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001; 50: 427-434.
31. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
32. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
33. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-1627.
34. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2119.
35. Heriot AG, Byrne CM, Lee P, Dobbs B, Tilney H, Solomon MJ, et al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum 2008; 51: 284-291.
36. Bhangu A, Brown G, Akmal M, Tekkis P,. Outcome of abdominosacral resection for locally advanced primary and recurrent rectal cancer. Br J Surg 2012; 99: 1453-1461.
37. Smith JD, Nash GM, Weiser MR, Temple LK, Guillem JG, Paty PB,. Multivisceral resections for rectal cancer. Br J Surg 2012; 99: 1137-1143.
38. Wilson RJ, Davies S, Yates D, Redman J, Stone M,. Impaired functional capacity is associated with all-cause mortality after major elective intra-abdominal surgery. Br J Anaesth 2010; 105: 297-303.
39. Ferenschild FT, Vermaas M, Verhoef C, Dwarkasing RS, Eggermont AM, de Wilt JH,. Abdominosacral resection for locally advanced and recurrent rectal cancer. Br J Surg 2009; 96: 1341-1347.
40. Sagar PM, Gonsalves S, Heath RM, Phillips N, Chalmers AG,. Composite abdominosacral resection for recurrent rectal cancer. Br J Surg 2009; 96: 191-196.
41. Melton GB, Paty PB, Boland PJ, Healey JH, Savatta SG, Casas-Ganem JE, et al. Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results. Dis Colon Rectum 2006; 49: 1099-1107.
42. Dozois EJ, Privitera A, Holubar SD, Aldrete JF, Sim FH, Rose PS, et al. High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved? J Surg Oncol 2011; 103: 105-109.
43. Moore HG, Shoup M, Riedel E, Minsky BD, Alektiar KM, Ercolani M, et al. Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum 2004; 47: 1599-1606.
44. Austin KK, Young JM, Solomon MJ,. Quality of life of survivors after pelvic exenteration for rectal cancer. Dis Colon Rectum 2010; 53: 1121-1126.
45. Bhangu A, Ali M, Cunningham D, Brown G, Tekkis P,. Comparison of long-term survival outcomes of operative versus non-operative management of recurrent rectal cancer. In print, Colorectal Dis 2013; 15: 156-163.
46. Salo JC, Paty PB, Guillem J, Minsky BD, Harrison LB, Cohen AM,. Surgical salvage of recurrent rectal carcinoma after curative resection: a 10-year experience. Ann Surg Oncol 1999; 6: 171-177.
47. Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I,. Surgery for locally recurrent rectal cancer. Dis Colon Rectum 2005; 48: 929-937.
48. Koda K, Tobe T, Takiguchi N, Oda K, Ito H, Miyazaki M,. Pelvic exenteration for advanced colorectal cancer with reconstruction of urinary and sphincter functions. Br J Surg 2002; 89: 1286-1289.
49. Hainsworth A, Al Akash M, Roblin P, Mohanna P, Ross D, George ML,. Perineal reconstruction after abdominoperineal excision using inferior gluteal artery perforator flaps. Br J Surg 2012; 99: 584-588.
50. Peacock O, Pandya H, Sharp T, Hurst NG, Speake WJ, Tierney GM, et al. Biological mesh reconstruction of perineal wounds following enhanced abdominoperineal excision of rectum (APER). Int J Colorectal Dis 2012; 27: 475-482.
51. Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, et al.; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 2009; 133: 1539-1551.
52. Harris DA, Davies M, Lucas MG, Drew P, Carr ND, Beynon J; Swansea Pelvic Oncology Group. Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg 2011; 98: 582-588.
53. Habr-Gama A, Perez RO, Proscurshim I, Rawet V, Pereira DD, Sousa AH, et al. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon Rectum 2008; 51: 277-283.
54. Sprenger T, Rothe H, Homayounfar K, Beissbarth T, Ghadimi BM, Becker H, et al. Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens-results from a prospective evaluation with extensive pathological work-up. J Gastrointest Surg 2010; 14: 96-103.
55. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753-3760.
56. Bhangu A, Ali SM, Darzi A, Brown G, Tekkis P,. Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. Colorectal Dis 2012; 14: 1457-1466.
57. Tilney HS, Rasheed S, Northover JM, Tekkis PP,. The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery. Dis Colon Rectum 2009; 52: 1723-1729.
58. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH; Pathology Review Committee; Cooperative Clinical Investigators. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Path 2002; 26: 350-357.
59. Thaysen HV, Jess P, Laurberg S,. Health-Related Quality of Life after surgery for primary advanced rectal cancer and recurrent rectal cancer: a review. Colorectal Dis 14: 797-803.
60. Palmer G, Martling A, Lagergren P, Cedermark B, Holm T,. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann Surg Oncol 2008; 15: 3109-3117.
61. Kakuda JT, Lamont JP, Chu DZ, Paz IB,. The role of pelvic exenteration in the management of recurrent rectal cancer. Am J Surg 2003; 186: 660-664.
62. Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ; Intergroup Study 0114. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol 2003; 21: 3623-3628.
63. Ngan SY, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, et al. Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis Colon Rectum 2005; 48: 1389-1396.
64. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. The New England journal of medicine 1991; 324: 709-715.
65. Salerno G, Daniels IR, Brown G,. Magnetic resonance imaging of the low rectum: defining the radiological anatomy. Colorectal Dis 2006; 8 (Suppl. 3): 10-13.
66. Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 2009; 9: 50.
67. Association of Coloproctology of Great Britain and Ireland. Guidelines for the Management of Colorectal Cancer, 3rd edn. Association of Coloproctology of Great Britain and Ireland: London, 2007.
68. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK,. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-271.
69. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646.
70. Memon S, Keating JP, Cooke HS, Dennett ER,. A study into external rectal anatomy: improving patient selection for radiotherapy for rectal cancer. Dis Colon Rectum 2009; 52: 87-90.
71. Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE,. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 1354-1362.
72. Ogunbiyi OA, McKenna K, Birnbaum EH, Fleshman JW, Kodner IJ,. Aggressive surgical management of recurrent rectal cancer-is it worthwhile? Dis Colon Rectum 1997; 40: 150-155.
73. Wanebo HJ, Antoniuk P, Koness RJ, Levy A, Vezeridis M, Cohen SI, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum 1999; 42: 1438-1448.
74. de Chaisemartin C, Penna C, Goere D, Benoist S, Beauchet A, Julie C, et al. Presentation and prognosis of local recurrence after total mesorectal excision. Colorectal Dis 2009; 11: 60-66.
75. Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O'Connell MJ, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg 2003; 237: 502-508.
76. You YN, Habiba H, Chang GJ, Rodriguez-bigas MA, Skibber JM,. Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer. Ann Surg Oncol 2011; 18: 989-996.
77. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP,. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009; 18: 15-24.
78. Suzuki K, Dozois RR, Devine RM, Nelson H, Weaver AL, Gunderson LL, et al. Curative reoperations for locally recurrent rectal cancer. Dis Colon Rectum 1996; 39: 730-736.
79. Yamada K, Ishizawa T, Niwa K, Chuman Y, Akiba S, Aikou T,. Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Br J Surg 2001; 88: 988-993.
80. Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B, et al.; International Rectal Cancer Study Group (IRCSG). International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg 2010; 34: 2689-2700.
81. Shihab OC, Taylor F, Salerno G, Heald RJ, Quirke P, Moran BJ, et al. MRI Predictive Factors for Long-Term Outcomes of Low Rectal Tumours. Ann Surg Oncol 2011; 18: 3278-3784.
82. Messiou C, Chalmers AG, Boyle K, Wilson D, Sagar P,. Pre-operative MR assessment of recurrent rectal cancer. Br J Radiol 2008; 81: 468-473.
83. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308.
84. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL,. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging 2004; 29: 663-668.
85. Puli SR, Reddy JB, Bechtold ML, Choudhary A, Antillon MR, Brugge WR,. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol 2009; 16: 1255-1265.
86. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333: 779.
87. Dent OF, Chapuis PH, Haboubi N, Bokey L,. Magnetic resonance imaging cannot predict histological tumour involvement of a circumferential surgical margin in rectal cancer. Colorectal Dis 2011; 13: 974-981.
88. Davey K, Heriot AG, Mackay J, Drummond E, Hogg A, Ngan S, et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 2008; 51: 997-1003.
89. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-5130.
90. Mak AC, Rich TA, Schultheiss TE, Kavanagh B, Ota DM, Romsdahl MM,. Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid. Int J Radiat Oncol Biol Phys 1994; 28: 597-603.
91. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005; 23: 5620-5627.
92. Garofalo M, Moughan J, Hong T, Bendell J, Berger A, Lerma F, et al. RTOG 0822: A Phase II Study of Preoperative (preop) Chemoradiotherapy (CRT) Utilizing IMRT in Combination with Capecitabine (C) and Oxaliplatin (O) for Patients (pts) with Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 81(2):S6; ASTRO 2011 proceeding.
93. Vuong T, Belliveau PJ, Michel RP, Moftah BA, Parent J, Trudel JL, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum 2002; 45: 1486-1493.
94. Vestermark LW, Jacobsen A, Qvortrup C, Hansen F, Bisgaard C, Baatrup G, et al. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta oncologica 2008; 47: 428-433.
95. Hashiguchi Y, Sekine T, Sakamoto H, Tanaka Y, Kazumoto T, Kato S, et al. Intraoperative irradiation after surgery for locally recurrent rectal cancer. Dis Colon Rectum 1999; 42: 886-893.
96. Kusters M, Valentini V, Calvo FA, Krempien R, Nieuwenhuijzen GA, Martijn H, et al. Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases. Ann Oncol 2010; 21: 1279-1284.
97. Dubois JB, Bussieres E, Richaud P, Rouanet P, Becouarn Y, Mathoulin-Pélissier S, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. Radiother Oncol 2011; 98: 298-303.
98. Dobrowsky W,., Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. Br J Radiol 1992; 65: 143-147.
99. Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW, et al. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys 2001; 50: 1299-1308.
100. Mohiuddin M, Lingareddy V, Rakinic J, Marks G,. Reirradiation for rectal cancer and surgical resection after ultra high doses. Int J Radiat Oncol Biol Phys 1993; 27: 1159-1163.
101. Glimelius BL,. The role of preoperative and postoperative radiotherapy in rectal cancer. Clin Colorectal Cancer 2002; 2: 82-92.
102. Bujko K, Nowacki MP, Oledzki J, Sopylo R, Skoczylas J, Chwalinski M,. Sphincter preservation after short-term preoperative radiotherapy for low rectal cancer-presentation of own data and a literature review. Acta Oncol 2001; 40: 593-601.
103. Gerard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
104. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M,. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223.
105. Mawdsley S, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, et al. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005; 63: 745-752.
106. Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1081-1086.
107. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780.
108. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125.
109. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-248.
110. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-865.
111. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
112. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J,. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009; 52: 1927-1934.
113. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Marks G,. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994; 30: 169-175.
114. Mohiuddin M, Mohiuddin MM, Marks J, Marks G,. Future directions in neoadjuvant therapy of rectal cancer: maximizing pathological complete response rates. Cancer Treat Rev 2009; 35: 547-552.
115. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 2011; 254: 486-493.
116. Wiig JN, Poulsen JP, Larsen S, Braendengen M, Waehre H, Giercksky KE,. Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer. Eur J Surg 2002; 168: 42-48.
117. Mannaerts GH, Rutten HJ, Martijn H, Groen GJ, Hanssens PE, Wiggers T,. Abdominosacral resection for primary irresectable and locally recurrent rectal cancer. Dis Colon Rectum 2001; 44: 806-814.
118. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009; 33: 1502-1508.
119. Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 2007; 14: 1870-1877.
120. Wasserman K., Diagnosing cardiovascular and lung pathophysiology from exercise gas exchange. Chest 1997; 112: 1091-1101.
121. Belardinelli R, Lacalaprice F, Carle F, Minnucci A, Cianci G, Perna G, et al. Exercise-induced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J 2003; 24: 1304-1313.
122. Older P, Hall A, Hader R,. Cardiopulmonary exercise testing as a screening test for perioperative management of major surgery in the elderly. Chest 1999; 116: 355-362.
123. Abbas SM, Hill AG,. Systematic review of the literature for the use of oesophageal Doppler monitor for fluid replacement in major abdominal surgery. Anaesthesia 2008; 63: 44-51.
124. Rödel C, Grabenbauer GG, Matzel KE, Schick C, Fietkau R, Papadopoulos T, et al. Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum 2000; 43: 312-319.
125. Wells BJ, Stotland P, Ko MA, Al-Sukhni W, Wunder J, Ferguson P, et al. Results of an aggressive approach to resection of locally recurrent rectal cancer. Ann Surg Oncol 2007; 14: 390-395.
126. Moriya Y, Akasu T, Fujita S, Yamamoto S,. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer. Surg Oncol Clin N Am 2005; 14: 225-238.
127. Han IH, Seo YJ, Cho WH, Choi BK,. Computer-assisted modified mid-sacrectomy for en bloc resection of chordoma and preservation of bladder function. J Korean Neurosurg Soc 2011; 50: 523-527.
128. Alektiar KM, Zelefsky MJ, Paty PB, Guillem J, Saltz LB, Cohen AM, et al. High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 2000; 48: 219-226.
129. Lowy AM, Rich TA, Skibber JM, Dubrow RA, Curley SA,. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996; 223: 177-185.
130. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, et al. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 2002; 85: 285-291.
131. Wanebo HJ, Belliveau J, Begossi G, Levy A,. Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer. Colorectal Dis 2003; 5: 508-514.
132. Hinojosa MW, Parikh DA, Menon R, Wirth GA, Stamos MJ, Mills S,. Recent experience with abdominal perineal resection with vertical rectus abdominis myocutaneous flap reconstruction after preoperative pelvic radiation. Am Surg 2009; 75: 995-999.
133. Christensen HK, Nerstrom P, Tei T, Laurberg S,. Perineal repair after extralevator abdominoperineal excision for low rectal cancer. Dis Colon Rectum 2011; 54: 711-717.
134. Anderin C, Martling A, Lagergren J, Ljung A, Holm T,. Short term outcome after gluteus maximus myocutaneous flap reconstruction of the pelvic floor following extra-levator abdominoperineal excision of the rectum. Colorectal Dis 2011; 14: 1060-1064.
135. Holm T, Cedermark B, Rutqvist LE,. Local recurrence of rectal adenocarcinoma after 'curative' surgery with and without preoperative radiotherapy. Br J Surg 1994; 81: 452-455.
136. Nisar PJ, Scott HJ,. Myocutaneous flap reconstruction of the pelvis after abdominoperineal excision. Colorectal Dis 2009; 11: 806-816.
137. Han JG, Wang ZJ, Gao ZG, Xu HM, Yang ZH, Jin ML,. Pelvic floor reconstruction using human acellular dermal matrix after cylindrical abdominoperineal resection. Dis Colon Rectum 2010; 53: 219-223.
138. Boereboom CL, Watson NF, Sivakumar R, Hurst NG, Speake WJ,. Biological tissue graft for pelvic floor reconstruction after cylindrical abdominoperineal excision of the rectum and anal canal. Tech Coloproctol 2009; 13: 257-258.
139. Vaughan-Shaw PG, King AT, Cheung T, Beck NE, Knight JS, Nichols PH, et al. Early experience with laparoscopic extralevator abdominoperineal excision within an enhanced recovery setting: analysis of short-term outcomes and quality of life. Ann R Coll Surg Engl 2011; 93: 451-459.
140. Morris EJ, Maughan NJ, Forman D, Quirke P,. Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist. J Clin Oncol 2007; 25: 2573-2579.
141. Pacelli F, Tortorelli AP, Rosa F, Bossola M, Sanchez AM, Papa V, et al. Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy. Ann Surg Oncol 2010; 17: 152-162.
142. Rahbari NN, Ulrich AB, Bruckner T, Münter M, Nickles A, Contin P, et al. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? Ann Surg 2011; 253: 522-533.
143. Edden Y, Wexner SD, Berho M,. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. Colorectal Dis 2012; 14: 555-561.
144. Grossmann I, de Bock GH, Meershoek-Klein Kranenbarg WM, van de Velde CJ, Wiggers T. Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. Eur J Surg Oncol 2007; 33: 183-187.
145. Renehan AG, Egger M, Saunders MP, O'Dwyer ST,. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324: 813.
146. National Institute of Clinical Excellence. Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer. Clinical Guidelines. November 2011. http://www.nice.org.uk/nicemedia/live/13597/56957/56957.pdf [November 2011].
147. Bernstein TE, Endreseth BH, Romundstad P, Wibe A,. Improved local control of rectal cancer reduces distant metastases. Colorectal Dis 2012; 14: e668-e678.
148. Bakx R, Visser O, Josso J, Meijer S, Slors JF, van Lanschot JJ,. Management of recurrent rectal cancer: a population based study in greater Amsterdam. World J Gastroenterol 2008; 14: 6018-6023.
149. Ito Y, Ohtsu A, Ishikura S, Boku N, Nihei K, Ogino T, Boku N, Nihei K, Ogino T, et al. Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer. Jpn J Clin Oncol 2003; 33: 180-185.